STOCK TITAN

Zentek Announces Management Transition

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management

Zentek (NASDAQ:ZTEK) announced that CEO Greg Fenton's consulting contract will not be extended beyond its expiration date of March 31, 2026. The board of directors has initiated a search for his successor, while the current executive team continues to lead the company in the interim.

Fenton served as CEO for seven years, during which he guided the company's growth and diversification. The board emphasized its commitment to appointing a new CEO who will focus on transitioning Zentek from research and development to commercialization.

Loading...
Loading translation...

Positive

  • Company signals strategic shift towards commercialization phase
  • Orderly transition process with advance notice of leadership change

Negative

  • Uncertainty during CEO transition period
  • Loss of experienced leadership with 7-year tenure

News Market Reaction 1 Alert

-11.52% News Effect

On the day this news was published, ZTEK declined 11.52%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

GUELPH, ON / ACCESS Newswire / July 11, 2025 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property technology development and commercialization company, announces that the board of directors has determined not to extend the consulting contract for Greg Fenton, the Company's Chief Executive Officer and a Director of the Company, when the term expires on March 31, 2026. The Company has begun its search for Mr. Fenton's successor, and, until such successor has been appointed, the Company's current executive team will continue to lead the Company.

"On behalf of the Board, I want to thank Greg for guiding Zentek on its path of growth and diversification over the past seven years, and for his stewardship of the business," said Eric Wallman, Chairman of the board of directors. "The board of directors is committed to ensuring that the new Chief Executive Officer will drive Zentek's transition from research and development to commercialization."

About Zentek Ltd.

Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener.

Zentek's patented technology platform ZenGUARD™, is shown to significantly increase the bacterial and viral filtration efficiency for surgical masks and aims to do the same with HVAC (heating, ventilation, and air conditioning) filters. Zentek's ZenGUARD™ production facility is in Guelph, Ontario.

Zentek, through its wholly owned subsidiary, Triera Biosciences Ltd., has a global exclusive licence to the aptamer-based platform technology developed by McMaster University, which is being jointly developed by Zentek and McMaster for both the diagnostic and therapeutic markets.

For further information:

investorrelations@zentek.com

Ryan Shacklock
Email:rshacklock@zentek.com
306-270-9610

To find out more about Zentek, please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR+ profile at http://www.sedarplus.ca/.

Forward-Looking Statements

This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Zentek Ltd.



View the original press release on ACCESS Newswire

FAQ

When is Zentek (ZTEK) CEO Greg Fenton leaving the company?

Greg Fenton's consulting contract will expire on March 31, 2026 and will not be extended by the board of directors.

Who will replace Greg Fenton as Zentek's CEO?

The board has initiated a search for a new CEO. In the meantime, the current executive team will continue to lead the company.

How long was Greg Fenton CEO of Zentek (ZTEK)?

Greg Fenton served as CEO of Zentek for seven years, leading the company's growth and diversification efforts.

What is Zentek's (ZTEK) strategic direction after the CEO change?

The board is focused on appointing a new CEO who will drive Zentek's transition from research and development to commercialization.

What type of company is Zentek (ZTEK)?

Zentek is an intellectual property technology development and commercialization company listed on both NASDAQ and TSX-V exchanges.
Zentek Ltd

NASDAQ:ZTEK

ZTEK Rankings

ZTEK Latest News

ZTEK Latest SEC Filings

ZTEK Stock Data

78.33M
101.45M
6.1%
1.47%
0.08%
Medical Instruments & Supplies
Healthcare
Link
Canada
Guelph